Elanco Animal Health (ELAN) Stock News

Elanco Animal Health (NYSE:ELAN) has scheduled its second quarter 2025 financial results announcement for Thursday, August 7, 2025. The company will host a conference call at 8:00 a.m. Eastern time to discuss the results with investors, media, and the general public.

A live webcast of the conference call will be accessible through Elanco's investor relations website, with a replay available shortly after the event concludes.

Elanco Animal Health (NYSE:ELAN) has received USDA approval for TruCan™ Ultra CIV H3N2/H3N8, a groundbreaking canine influenza vaccine. The vaccine is the only ½ mL bivalent CIV vaccine offering protection against both H3N2 and H3N8 strains, achieving 100% virus neutralization against 33 current field isolates.

Key clinical achievements include zero lung lesions in vaccinated dogs post H3N2 challenge and proven reduction in viral shedding. The vaccine is particularly significant for high-risk breeds, including brachycephalic dogs, and completes Elanco's Tru Portfolio of vaccines featuring PureFil™ Technology. The product is now available for pre-order with shipping expected within 30 business days.

Neurizon Therapeutics has entered into an exclusive global licensing agreement with Elanco Animal Health (NYSE:ELAN) for Monepantel, the key ingredient in NUZ-001, their lead investigational therapy for ALS and other neurodegenerative diseases.

The agreement includes exclusive worldwide rights to Elanco's intellectual property, access to non-clinical studies and manufacturing data, and outlines terms for a future GMP-compliant Monepantel supply agreement. Financial terms include a nominal upfront fee, development milestone payments of $9.75 million for initial products and $5.2 million for subsequent products, sales milestones up to $65 million, and single-digit royalties on global net sales.

A formal supply agreement is expected to be finalized in H2 2025, which will provide Neurizon with a long-term source of GMP-compliant monepantel for clinical development and commercialization.

Elanco Animal Health (NYSE:ELAN) has released its 2024 Impact Report, introducing a new framework focused on four key communities: animals, customers, society, and employees. The company achieved significant milestones including $461 million in innovation revenue from new products like Zenrelia and Credelio Quattro, exceeding their target of $420-450 million.

Key achievements include becoming the #1 retail parasiticide dispenser in the U.S., launching Bovaer® for methane reduction in dairy cattle, and enrolling 11% of U.S. dairy herds in their UpLook sustainability database. The company demonstrated strong social impact through $400,000 in product donations, 26,000 volunteer hours, and improved employee engagement scores of 71% in Q1 2025.

Elanco Animal Health (ELAN) has received a positive opinion from the EU's Committee for Veterinary Medicinal Products for Zenrelia (ilunocitinib), a treatment for pruritus associated with allergic dermatitis and atopic dermatitis in dogs. The CVMP's recommendation, based on demonstrated quality, safety, and efficacy, sets the stage for EU marketing authorization within 60 days. Notably, Zenrelia is Elanco's fastest globalized product, with eight major regulatory approvals expected in just 18 months. The company has conducted a successful head-to-head non-inferiority study versus the market incumbent. Already available in Brazil, Canada, Japan, and the United States, Elanco plans to launch Zenrelia in the EU market before the end of Q3 2025, with additional approvals expected in Australia and the UK in 2025.

Elanco Animal Health (ELAN) has released a groundbreaking report highlighting the widespread issue of canine itchiness in America. The study reveals that 90% of U.S. dogs experience itchiness, with 83% showing increased symptoms during allergy seasons. Pet owners typically wait 6 weeks before seeking veterinary care and spend an average of $173 more during allergy season on treatments. The report emphasizes the emotional and financial toll on pet owners, with 53% feeling judged and 75% feeling hopeless when treatments fail. The study also identifies America's "Itchiest Cities," with Memphis pet owners spending $548 annually on itch treatments compared to the national average of $302. Elanco promotes their new product Zenrelia (ilunocitinib tablets) as a once-daily, cost-effective solution for canine itch relief.

Elanco Animal Health (NYSE: ELAN) has appointed Robert VanHimbergen as Executive Vice President and Chief Financial Officer, effective July 7, 2025. VanHimbergen, currently CFO at Hillenbrand, Inc., brings nearly three decades of finance leadership experience, including 15 years at Johnson Controls where he held various executive positions. He succeeds Todd Young, who will remain as an advisor through August 31, 2025.

The company is experiencing strong momentum with seven consecutive quarters of growth and is focusing on accelerating growth, globalizing innovation, expanding margins, and improving cash generation. Elanco also reconfirmed its second quarter and full year guidance issued during the May 7, 2025 earnings call.

Elanco Animal Health (NYSE: ELAN) has announced its management's participation in two upcoming investor conferences. CEO Jeff Simmons will attend the BNP Paribas 2nd Annual Animal Health Day on May 22, 2025, at 12:00 p.m. ET. Additionally, both Simmons and CFO Todd Young will participate in a fireside chat at the Stifel 2025 Jaws & Paws Conference on May 29, 2025, at 8:00 a.m. ET.

Both events will feature live audio webcasts accessible through Elanco's investor website under the "Events and Presentations" section, with replays available for a limited time after each event.

Elanco Animal Health (NYSE: ELAN) reported Q1 2025 results with revenue of $1,193 million, showing a 1% decline year-over-year but 4% organic constant currency growth. The company achieved reported net income of $67 million and adjusted net income of $184 million, with reported EPS of $0.13 and adjusted EPS of $0.37. Elanco raised its 2025 revenue guidance to $4,510-$4,580 million, maintaining adjusted EBITDA guidance of $830-$870 million. Key highlights include strong performance in Farm Animal segment, accelerating Pet Health trends, and progress in debt reduction with expected gross debt paydown of $450-$500 million in 2025. The company improved its year-end net leverage ratio target to 3.9x-4.3x, supported by working capital management and a $295 million lotilaner U.S. royalty monetization deal.